What Can Digital Health Innovators Learn from Oncology? (Sean Khozin)

Faces of Digital Health

Therapies for cancer are being developed at light speed and upward of 60 gene and cell therapies are projected to reach regulatory approval in the U.S. by 2030, according to the MIT NEWDIGS collaborative. Due to the nature of cancer, readiness for risks in drug development is much higher here than it might be in other medical fields. In this episode you’re going to hear a bit more about what can digital health innovation learn from the mindset present in oncology development.

Sean Khozin is the CEO of CancerLinQ, a non-profit health technology company focused on improving quality of care and health outcomes for all patients with cancer. He was the Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, before that he co-founded Hello Health, a technology company focused on developing integrated telemedicine, point-of-care data visualization, and advanced analytical systems for optimizing patient care and clinical research. He was also the Founding director of a digital health incubator inside the FDA.

You will hear a little bit about processes in oncology, innovation in oncology, the promise of decentralized clinical trials and more.

Leave a rating or review: lovethepodcast.com/facesofdigitalhealth